They were supposed to talk about the patent system driving up drug prices. But most lawmakers got distracted by small tweaks.

7 May 2019 - If there was any hope that Congress might overhaul the way this country doles out the ...

Read more →

‘One-and-done’ for new drugs could cut patent thickets and boost generic competition

11 February 2019 - In a perfect world, the system for conveying medications from their makers to patients should be ...

Read more →

Patent abuse is driving up drug prices. Just look at Lantus.

7 December 2018 -  A rare point of consensus following the midterm elections is that Americans are adamant about lowering ...

Read more →

Competition watchdog’s appeal over Pfizer ruling dismissed

19 October 2018 - The High Court has dismissed the ACCC’s application to appeal a decision on whether Pfizer’s local ...

Read more →

AbbVie announces global resolution of Humira (adalimumab) patent disputes with Fresenius Kabi

18 October 2018 - Agreements provide non-exclusive license to Fresenius Kabi for Humira related intellectual property in the U.S. effective 30 ...

Read more →

Truvada ruling could allow cheap HIV prevention in the UK

19 September 2018 - Cheap copies of Gilead’s HIV drug Truvada, which can also be used to reduce the risk ...

Read more →

Promoting patient interests in implementing the Federal Right to Try Act

13 August 2018 - On May 30, 2018, President Trump signed into law the federal Right to Try Act of 2017,1 ...

Read more →

Paediatric exclusivity and regulatory authority

8 November 2017 - In May 2017, the US FDA denied a 6-month extension of market exclusivity for Sensipar (cinacalcet), ...

Read more →

Another small victory for Australian Government in its pursuit of damages for PBS over-payments during interlocutory injunction period

4 May 2017 - The Australian Government has had another small victory in the most recent interlocutory decision in the clopidogrel ...

Read more →

Changes to pharmaceutical extension of term application procedures the latest front in the battle for savings in Australia’s health care budget

26 April 2017 - It’s no secret that the Australian Government is struggling to manage the cost of its health ...

Read more →

Full Federal Court confirms an application to list medicine on the PBS prior to patent expiry is a non-infringing act

19 April 2017 - Late last week, the Full Federal Court of Australia confirmed that the mere act of filing a ...

Read more →

How patent trolls sparked a failed assault on high drug prices

11 April 2017 - Kyle Bass caused high anxiety for big pharma. ...

Read more →

Bass battled U.S. drug patents and prices but lost to ‘Cabal’

10 April 2017 - Hedge fund manager says he raised awareness of high drug costs. ...

Read more →

Federal Court of Australia dismisses preliminary discovery application regarding biosimilar suspected of infringing manufacturing process patents

26 March 2017 - In the recent decision of Pfizer Ireland Pharmaceuticals v Samsung Bioepis, Justice Stephen Burley of the Federal ...

Read more →

TPP: no reason big pharma supply would stop

26 April 2016 - Trade Minister Todd McClay says he sees no reason why big pharmaceutical firms would stop supplying ...

Read more →